MedTrace Logo

The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes

NCT03249259 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-10-08

No results posted yet for this study

Summary

In this study, the investigators are going to investigate the efficacy of choline alfoscerate on improvement of cognitive function assessed by MMSE compared to plaebo.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Choline alfoscerate

Treatment duration is 6 months and can be extended to 12 months with participant's agreement.

DRUG

Placebo

Treatment duration is 6 months and can be extended to 12 months with participant's agreement.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-10
Primary Completion
2019-06-30
Completion
2019-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249259 on ClinicalTrials.gov